MediPharm Labs Corp.

TSX:LABS Voorraadrapport

Marktkapitalisatie: CA$28.8m

MediPharm Labs Toekomstige groei

Future criteriumcontroles 2/6

MediPharm Labs is forecast to grow revenue at 28.8% per annum. EPS is expected to grow by 123% per annum.

Belangrijke informatie

n/a

Groei van de winst

123.0%

Groei van de winst per aandeel

Pharmaceuticals winstgroei54.4%
Inkomstengroei28.8%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt16 Sep 2024

Recente toekomstige groei-updates

Recent updates

MediPharm Labs Corp. (TSE:LABS) Doing What It Can To Lift Shares

Oct 11
MediPharm Labs Corp. (TSE:LABS) Doing What It Can To Lift Shares

MediPharm Labs (TSE:LABS) Is Using Debt Safely

May 29
MediPharm Labs (TSE:LABS) Is Using Debt Safely

Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Mar 23
Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Jan 10
Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Sep 06
MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Apr 17
MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Aug 20
Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

May 21
Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

Apr 06
Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Mar 07
Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Aug 18
Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates

May 23
Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates

Reflecting on MediPharm Labs' (TSE:LABS) Share Price Returns Over The Last Year

Jan 11
Reflecting on MediPharm Labs' (TSE:LABS) Share Price Returns Over The Last Year

Winst- en omzetgroeiprognoses

TSX:LABS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CAD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202558N/AN/AN/A1
12/31/202446N/AN/AN/A1
6/30/202438-13-5-5N/A
3/31/202437-14-11-11N/A
12/31/202333-13-13-12N/A
9/30/202330-16-15-14N/A
6/30/202328-20-14-14N/A
3/31/202323-26-14-14N/A
12/31/202222-30-17-16N/A
9/30/202222-46-21-20N/A
6/30/202220-46-18-17N/A
3/31/202221-48-13-13N/A
12/31/202122-55-14-13N/A
9/30/202122-64-17-16N/A
6/30/202122-72-27-26N/A
3/31/202130-63-33-28N/A
12/31/202036-66-45-38N/A
9/30/202062-39-46-29N/A
6/30/2020101-20-67-40N/A
3/31/2020118-15-74-45N/A
12/31/20191292-58-25N/A
9/30/20191071-54-27N/A
6/30/201964-4-36-12N/A
3/31/201932-8-23-4N/A
12/31/201810-8-26-11N/A
9/30/2018N/A-6-23-10N/A
6/30/2018N/A-4-9-4N/A
3/31/2018N/A-2N/A-3N/A
12/31/2017N/A-1N/A0N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if LABS's forecast earnings growth is above the savings rate (2.2%).

Winst versus markt: Insufficient data to determine if LABS's earnings are forecast to grow faster than the Canadian market

Hoge groeiwinsten: Insufficient data to determine if LABS's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: LABS's revenue (28.8% per year) is forecast to grow faster than the Canadian market (6.9% per year).

Hoge groei-inkomsten: LABS's revenue (28.8% per year) is forecast to grow faster than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if LABS's Return on Equity is forecast to be high in 3 years time


Ontdek groeibedrijven